All Drug Discovery Processes articles
-
Company profileLight-powered reaction converts sulfonamides into drug discovery building blocks
A light-driven chemical reaction developed at Florida State University can strip sulfur atoms from sulfonamides to produce anilines, offering a new route to repurpose previously intractable compounds for drug discovery.
-
NewsFramework proposed to advance plant-derived anti-inflammatory drug discovery
A review led by researchers at the Naval Medical University proposes a structured framework for evaluating plant-derived anti-inflammatory compounds, warning that pathway inhibition alone is insufficient evidence of direct molecular target engagement.
-
ArticleStrong binding isn’t enough – why cellular target engagement matters
Promising compounds don’t always engage their targets in living cells. At ELRIG Drug Discovery 2026, Dr Joshua Sopp of Promega discusses why earlier cellular testing matters and how BRETSA could help researchers investigate new drug targets.
-
ReportLab Automation 2026: Inside the labs making drug discovery faster and more reliable
Six scientists and industry experts discuss the challenges of automating drug discovery, from improving screening reliability and reproducibility to developing more autonomous laboratories.
-
NewsNovel RNA-protein interactions reveal conserved SARS-CoV-2 antiviral targets
A new study has mapped previously unknown RNA-protein interactions across the SARS-CoV-2 genome, identifying conserved sites involving RdRp and the nucleocapsid protein as potential antiviral drug targets less susceptible to mutational escape.
-
ArticleVirtual cells vs experimental models: which can you trust?
How reliable are AI virtual cells compared with experimental models? We examine what each can predict or measure, the evidence behind their reliability and their role in early drug discovery.
-
ArticleWhy reagent selection belongs inside assay design
High affinity is often a priority when selecting reagents, but does it guarantee better assay performance? Discover why binding kinetics and matrix selectivity matter when developing custom reagents for challenging targets.
-
InterviewHow multiomics can strengthen drug target discovery
How can multiomics help researchers identify more promising drug targets? Dr Shi-qi An explores how combining molecular data can reveal therapeutic vulnerabilities and mechanisms of drug resistance.
-
News3D Cell Painting reveals cancer drug differences missed in 2D
Two cancer drugs appeared almost identical in conventional screening, but a new 3D Cell Painting method exposed striking differences in their effects, raising questions about what 2D models might miss.
-
ArticleEarlier MSA detection could guide alpha-synuclein drug discovery
MSA and Parkinson’s share the same protein pathology, yet MSA progresses far faster. Could earlier detection reveal why and help researchers identify more effective targets for drug discovery?
-
NewsMLY2 and MLY8 compounds show promise as ulcerative colitis treatment candidates
Two experimental compounds derived from a phase II metabolite have demonstrated improved anti-inflammatory activity in preclinical models of ulcerative colitis.
-
InterviewA sceptical guide to AI agents in drug discovery
AI agents promise to transform drug discovery, but where do they really add value? Dr Eric Ma examines search, model choice, vendor lock-in and why scientific expertise matters more than ever.
-
ArticleDrug discovery in Q3 2026 – what changed and why it matters
Agentic AI, ultralarge virtual screening, molecular glues and human-relevant models were among the key developments in early drug discovery during Q3 2026. Drug Target Review examines what changed, why it matters and what to watch heading into Q4.
-
ArticleInduced proximity drugs – why complex formation is not enough
A drug can form exactly the complex it was designed to make and still fail to work. Two recently approved induced proximity drugs show why what happens after complex formation – not formation alone – can decide the outcome.
-
ArticleAI agents vs scientists: what should we automate in drug discovery?
AI agents can search, analyse and plan across drug discovery workflows, but where should scientists hand over control? We examine what to automate, what to check and where human judgement matters most.
-
ArticleHow protective gene variants are revealing new drug targets
Finding the right drug target remains one of discovery’s biggest challenges. Human genetics is helping researchers strengthen the evidence before committing years of research and investment.
-
NewsWhat SIRPα reveals about how breast cancer takes hold in the brain
Scientists at Wake Forest University School of Medicine have uncovered a previously unrecognised cancer-intrinsic role for SIRPα in triple-negative breast cancer, linking the cell-surface protein to mitochondrial fission, tumour-cell migration and suppression of the brain’s immune defences.
-
ArticleWhy AI struggles with new drug targets – and how physics could help
Virtual screening can assess billions of compounds, but performance can fall on unfamiliar targets. Combining AI with molecular physics could help make predictions more reliable.
-
NewsInsilico Medicine launches open-source AI longevity research toolkit
Insilico Medicine has published a Cell cover study introducing LongevityBench, a suite of specialised AI models and an autonomous agentic discovery platform.
-
NewsNew malaria mutations linked to resistance against multiple front-line drugs
Whole-genome sequencing of parasites from Ugandan patients has uncovered a cluster of genetic variants linked to reduced susceptibility to multiple front-line malaria treatments, with researchers warning the mutations are spreading rapidly.